Marcelle Pick explains how Eli Lilly's tirzepatide works by mimicking GLP-1 and GIP hormones to suppress appetite and control blood sugar. Mounjaro treats diabetes with weight loss as a side effect, while ZepBound is the same drug marketed specifically for chronic weight management.
GLP-1 and GIP
ZepBound
Mounjaro
Turning our focus on Eli Lilly's contributions, Manjaro and Zip Bound, the newest one to come to the market, we see a fascinating development in this field. So Mounjaro containing Trisepatide has unique dualistic mechanisms. It not only mimics the GLP1 hormones which suppress appetite, but also the GIP hormone. And this dual action enhances effectiveness, affects your blood sugar and aids in weight loss significantly. And elilly leveraged his success to actually create Zepound, a drug specifically for chronic weight management that also uses a Triciaposide. And the key differences lie in Zeppelin focuses on weight management, while Monjiro is primarily a diabetes medication with weight loss as its significant benefit.
